How to Apply for Aptus Pharma IPO?

    Investors can apply for the Aptus Pharma IPO through their broker’s online trading platform or supported financial applications. The process involves logging into the trading account, navigating to the IPO section, and selecting Aptus Pharma IPO from the active list. Applicants then need to enter the number of lots they wish to apply for within the given price band, provide their UPI ID for payment, and confirm the details before submission. The UPI mandate must be approved before the cut-off time to ensure the application is valid.

    For complete details on this public offering, visit the Aptus Pharma IPO page on our website.

    Aptus Pharma IPO Application Process

    The Aptus Pharma IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

    Step 1: Login to Your Trading Platform

    Access your trading account using the broker's app or website.

    Step 2: Navigate to the IPO Section

    Go to the IPO section to view active IPO listings.

    Step 3: Select the Open IPO and Click Apply

    Locate Aptus Pharma IPO in the list of available IPOs and click the ‘Apply’ button.

    Step 4: Enter the Quantity of Shares You Wish to Apply For

    Specify the number of shares (minimum lot size: 2000 shares) within the price band of ₹65 to ₹70 per share.

    Step 5: Provide Your UPI ID

    Enter your UPI ID for payment authorization and ensure sufficient funds in your bank account.

    Step 6: Confirm the Application

    Review your application details and confirm the UPI mandate before 5 PM on the last application day.

    Step 7: Complete the Process and Wait for Allotment

    Submit the application and monitor the allotment status to check if shares have been allocated to you.

    Additional Read: Aptus Pharma IPO Investment Guide: Objectives & Opportunities

    About Aptus Pharma IPO: Overview and Key Facts

    Aptus Pharma Ltd, incorporated in 2010, is a pharmaceutical company engaged in the marketing and distribution of finished formulations across multiple therapeutic categories. Its portfolio includes medicines for gastrointestinal care, pain management, antibiotics, cardiology, diabetes, neuropsychiatry, dental, nutraceuticals, injectables, and general wellness. The business operates under four distinct divisions: Aptus Pharma for acute therapies, Aptus CD Care for chronic conditions, Aptus Wellcare for nutraceutical and wellness products, and Aptus Global for overseas markets.

    The company does not own manufacturing facilities but operates through a contract manufacturing model. It collaborates with seven partner units via a combination of formal agreements and purchase order-based arrangements. This approach enables Aptus Pharma to offer a wide variety of dosage forms such as tablets, capsules, softgels, syrups, and suspensions. As of March 2025, it managed 194 formulations in more than eleven therapeutic areas, supported by a warehousing setup and an extensive distribution network.

    The IPO is being launched to fund capital expenditure for office premises, furniture, and industrial racks, as well as to support working capital needs and general corporate purposes. The issue size is 18,60,000 shares, aggregating up to ₹13.02 crore, with shares proposed to be listed on SME BSE. The offering provides a closer look at how Aptus Pharma aims to strengthen its operational base while maintaining an asset-light business model through its distribution-driven strategy.

    To check your application status, visit the Aptus Pharma IPO Allotment Status page on Bajaj Broking’s website.

    Share this article: 

    Frequently Asked Questions

    Published Date : 17 Sep 2025

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    1 M+ Users

    4.8 App Rating

    4 Languages

    ₹7,300 Cr+ MTF Book

    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |